# Appendix 6
# Warnings in 1982 Package Insert

# 1982 Accutane Label

CONTRAINDICATIONS: Teratogenicity was observed in rats at a dose of isotretinoin of 150 mg/kg/day. In rabbits a dose of 10 mg/kg/day was teratogenic and embryotoxic and induced abortion. There are no adequate and well-controlled studies in pregnant women.

Because teratogenicity has been observed in animals given isotretinoin, patients who are pregnant or intend to become pregnant while undergoing treatment should not receive Accutane. Women of childbearing potential should not be given Accutane unless an effective form of contraception is used, and they should be fully counseled on the potential risks to the fetus should they become pregnant while undergoing treatment. Should pregnancy occur during treatment, the physician and patient should discuss the desirability of continuing the pregnancy.

WARNINGS: Although no abnormalities of the human fetus have been reported thus far, animal studies with retinoids suggest that teratogenic effects may occur. It is recommended that contraception be continued for one month or until a normal menstrual period has occurred following discontinuation of Accutane therapy.

PRECAUTIONS: Women of childbearing potential should be instructed to use an effective form of contraception when Accutane therapy is required. (See CONTRAINDICATIONS and WARNINGS.)

PATIENT INFORMATION BROCHURE: The following warning appeared inside the brochure and on the back cover of the brochure:

---

**Warning to Female Patients**

Because birth defects have been shown in experimental animals, you should not take Accutane if you are pregnant or intend to become pregnant while undergoing treatment. If you are of childbearing potential, be sure to use an effective form of contraception. Should you become pregnant, be sure to tell your doctor.

---